Activation of coagulation in C57BL/6 mice given verotoxin 2 (VT2) and the effect of co-administration of LPS with VT2

Thrombosis Research

Volumn 100, Issue 1, 2000, Pages 61-72

  Sugatani, Junko ^a   Igarashi, Takashi ^b   Munakata, Machiko ^c   Komiyama, Yutaka ^c   Takahashi, Hakuo ^c   Komiyama, Naoko ^a   Maeda, Toshio ^a   Takeda, Tae ^d   Miwa, Masao ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c KANSAI MEDICAL UNIVERSITY   (Japan)

^d NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Coagulation; LPS; Verotoxin 2 (VT2); Verotoxin producing Escherichia coli (VTEC)

Indexed keywords

LIPOPOLYSACCHARIDE; MESSENGER RNA; THROMBIN ANTITHROMBIN COMPLEX; VEROTOXIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING; BRAIN; CAUSE OF DEATH; DISEASE ASSOCIATION; DISEASE COURSE; ESCHERICHIA COLI; FIBRINOLYSIS; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; KIDNEY; KIDNEY FAILURE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ANIMAL; ANTITHROMBIN III; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BRAIN; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FIBRINOGEN; HEMORRHAGE; INTRACRANIAL HEMORRHAGES; KIDNEY; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; NEUTROPHILS; PEPTIDE HYDROLASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET COUNT; RNA, MESSENGER; SHIGA-LIKE TOXIN II; SHOCK; SUPPORT, NON-U.S. GOV'T; THROMBOPLASTIN; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0034306796     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00305-4     Document Type: Article

References (28)

1. Sporadic cases of haemolytic-uremic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools
2. Infection by verocytotoxin-producing Escherichia coli
3. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections
4. Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome
5. The coagulation cascade: Initiation, maintenance, and regulation
6. Type 1 plasminogen activator inhibitor
7. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
8. The fibrinolytic system in the hemolytic uremic syndrome: In vivo and in vitro studies
9. Activation of coagulation and fibrinolysis in childhood diarrhoea-associated haemolytic uremic syndrome
10. Impaired fibrinolysis in the hemolytic-uremic syndrome of childhood
11. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome
12. Shiga toxin-associated hemolytic uremic syndrome: Combined cytotoxic effects of Shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro
13. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: Implications for the pathogenesis of the hemolytic uremic syndrome
14. Purification and some properties of a Verotoxin from Escherichia coli O157:H7 that is immunologically unrelated to Shiga toxin
15. Biological consequences of thrombin receptor deficiency in mice
16. Low levels of tissue factor are compatible with development and hemostasis in mice
17. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
18. Hormonal regulation of prostaglandin F2α receptor gene expression in mouse ovary
19. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator
20. The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1
21. Neuronal and vascular pathology produced by verocytotoxin 2 in the rabbit central nervous system
22. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections
23. A simple method for determination of the factor VII-phospholipid complex using normotest
24. Increased activity of factor VII and factor VII-phospholipid complex measured using a normotest system in subjects with hyperlipidemia
25. Fibrin enhances the expression of IL-1β by human peripheral blood mononuclear cells
26. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products
27. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects
28. Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro